Microplate Luminometer measures flash and glow assays.
Press Release Summary:
Suited for life sciences research and diagnostic assays, SpectraMax® L features injection module that enables dual injection in 96- and 384-well microplates. For multi-user laboratories, unit contains AutoWash(TM) automated injector maintenance routine. SoftMax® Pro software provides data analysis for more than 120 assay protocols, while SoftMax® Pro GxP delivers data acquisition, analysis, and bioassay validation capabilities in GxP and FDA 21 CFR Part 11-compliant environment.
Original Press Release:
Molecular Devices Introduces SpectraMax® L Next-Generation Microplate Luminometer
SUNNYVALE, Calif., Jan. 10 /- Molecular Devices Corporation (NASDAQ:MDCC), a leader in innovative solutions for drug discovery and life sciences research, today announced the introduction of SpectraMax(R) L, a next-generation microplate luminometer for flash and glow luminescence assays. The new system is based on Molecular Devices' industry-leading SpectraMax(R) brand microplate reader platform, and will debut on January 28th, 2007 at the Laboratory Automation Conference in Palm Springs, California, Molecular Devices booth #243.
The SpectraMax(R) L microplate luminometer features a new optical system which provides increased sensitivity and greater dynamic range, making it ideal for life sciences research and diagnostic assays. The system also features an injector module, which enables researchers to perform dual injection in both 96- and 384-well microplates. For multi-user laboratories, the SpectraMax(R) L contains AutoWash(TM), an automated injector maintenance routine to ensure robust performance and reliability. The new system utilizes Molecular Devices' popular SoftMax(R) Pro data analysis software, which provides complete data analysis for more than 120 assay protocols. In addition, SpectraMax(R) L operates with SoftMax(R) Pro GxP software, the industry standard for powerful data acquisition, analysis and bioassay validation capabilities in a GxP and FDA 21 CFR Part 11-compliant environment.
Commenting on the launch, Joseph Machamer, Product Marketing Manager at Molecular Devices, stated, "SpectraMax(R) L is an optimum system for measuring flash and glow assays, including dual luciferase and acridinium ester flash assays. Dual injectors can be added to the system's base instrument in a 96-well configuration, as well as a new 384-well format, which has not been previously available. Additionally, the system features an ultra-fast photon counting technology, which allows a high signal-to-noise ratio and the lowest crosstalk in laboratory assays. Lastly, throughput can be increased to up to 50 plates per batch with the integration of our optional StakMax(TM) plate stacker."
Molecular Devices Corporation is a leading supplier of high-performance bioanalytical measurement systems that accelerate and improve drug discovery and other life sciences research. Molecular Devices' systems and consumables enable pharmaceutical and biotechnology companies to leverage advances in genomics, proteomics and parallel chemistry to facilitate the high-throughput and cost-effective identification and evaluation of drug candidates. Molecular Devices' solutions are based on its advanced core technologies that integrate its expertise in engineering, molecular and cell biology and chemistry. Molecular Devices enables its customers to improve research productivity and effectiveness, which ultimately accelerates the complex process of discovering and developing new drugs.
CONTACT: Tim Harkness of Molecular Devices Corporation, +1-408-747-3533
Web site: http://www.moleculardevices.com/
